Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
The tracker allows patients to report shortages of GLP-1 drugs by submitting their location and which brand of drug they are unable to access. The company plans to aggregate this data and publish updates to demonstrate to the FDA that supply shortages persist.
Andrew Dudum, co-founder and CEO of Hims & Hers, told the news outlet that more than 80,000 users on the company's platform have reported difficulty accessing these medications, a number that continues to grow.
This move follows the FDA's recent decision to remove tirzepatide, the active ingredient in Mounjaro, from its shortage list, and its ongoing evaluation of Novo Nordisk's semaglutide products.
Mr. Dudum argued that despite the declarations, drug manufacturers have not been able to meet demand, with large wholesalers such as McKesson and Cardinal Health echoing concerns about long-term supply shortages, according to the report.